Active Not RecruitingNCT05065294
Psilocybin therapy for people with bipolarity type II
About this title
Psilocybin Therapy for Depression in Bipolar II Disorder
Read the official source — NCT05065294Medication studyAges 18–70United States
Understand this study
Who could participate?
This study is for people with type II bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
- Listed locations
- San FranciscoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 28, 2022
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 14
- Sponsor
- University of California, San Francisco
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05065294
- Official title
Show the full official title
An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
San Francisco
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of California, San Francisco, a university.
Who can participate?
This study is for people with type II bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
